News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ablynx Release: Publication in Accordance With Article 14 of the Belgian Law of 2 May 2007 Regarding the Publication of Major Shareholdings



4/30/2012 8:35:08 AM

GHENT, BELGIUM--(Marketwire - April 27, 2012) - REGULATED INFORMATION

GHENT, Belgium, 27 April 2012 - Ablynx (EURONEXT BRUSSELS: ABLX) today announced, in accordance with Article 14 of the Belgian Law of 2 May 2007 regarding the publication of major shareholdings in issuers whose securities are admitted to trading on a regulated market (the "Transparency Law"), that it received a notification of shareholdings from vzw VIB.

The above shareholder now owns less than 3% in Ablynx.

Full versions of all transparency notifications are available on the website of Ablynx, section Investors.

About Ablynx

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies(®), a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has over 25 programmes in the pipeline and seven Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

Complete version of the press release: http://hugin.info/137912/R/1607016/509633.pdf

This announcement is distributed by Thomson Reuters on behalf of

Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Ablynx via Thomson Reuters ONE

[HUG#1607016]


For more information, please contact

Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e: Email Contact

Marieke Vermeersch
Investor Relations Manager
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: Email Contact

M:Communications:
Mary-Jane Elliott
Amber Bielecka
Claire Dickinson
t: +44 207 920 2330
e: Email Contact


Read at BioSpace.com


comments powered by Disqus
Ablynx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES